|
|
| |
Weight loss agents |
The definition of obesity
varies depending on what one reads, but in general, it is a chronic condition
defined by an excess amount body fat. A certain amount of body fat is
necessary for storing energy, heat insulation, shock absorption, and other
functions. The normal amount of body fat (expressed as percentage of body
fat) is between 25-30% in women and 18-23% in men. Women with over 30%
body fat and men with over 25% body fat are considered obese.
Obesity has reached epidemic proportions in the United States. One in
three Americans is obese. Obesity is also increasing rapidly throughout
the world, and the incidence of obesity has nearly doubled form 1991 to
1998.
Obesity is not just a cosmetic consideration; it is a dire health dilemma
directly harmful to one's health. In the United States, roughly 300,000
deaths per year are directly related to obesity, and more than 80% of
these deaths are in patients with a BMI (body mass index, which will be
discussed later in this article) over 30. Obesity also increases the risk
of developing a number of chronic diseases including: |
|
|
XENICAL
Generic name: Orlistat
Manufacturer: Roche (Switzerland)
|
|
Dosage |
Packing |
Price |
Pay now |
120 mg |
42 caps |
USD 95.00 |
|
|
|
|
RHODIOLA ROSEA
(dry roots)
|
 |
Dosage |
Packing |
Price |
Pay now |
|
28 g |
USD 15.00 |
|
Preparation of tea:
cut fine 5g of Rhodiola rosea roots. 1 cup of boiling water pour in roots
and leave for (brew) at least 4 hours. Than filter. Daily dosage: 1/5 cup - 3-5
times per day. For better taste dilute Rhodiola rosea tea with juice, tonic or
other herbal tea.
Preparation of tincture for personal usage: Mill
30 g of Rhodiola Rose roots in a coffee-grinder no less than 5-10 mm, add 150
ml of light spirits (30-40%), agitate and steep 3-5 days at room temperature.
Separate and filter the extract. Dosage: ? tsp. x 3 times per day.
RHODIOLA ROSEA
(dry extract tablets, total rosavins 40%)
|
 |
Health information and news
Dosage |
Packing |
Price |
Pay now |
50 mg |
60 tab |
USD 18.00 |
|
Dosage: 2 tablets 3 times daily
Course: 30 days, 180 tablets
|
|
 |
What Causes Obesity? |
|
The balance between
calorie intake and energy expenditure determines a person's weight. If
a person eats more calories than he or she burns, the person gains weight
(the body will store the excess energy as fat). If a person eats fewer
calories than he or she burns, he or she will lose weight. Therefore the
most common causes of obesity are overeating and physical inactivity.
At present, we know that there are many factors that contribute to obesity,
some of which have a genetic component:
• Genetics. A person is more likely to develop
obesity if one or both parents are obese. Genetics also affect hormones
involved in fat regulation. For example, one genetic cause of obesity
is leptin deficiency. Leptin is a hormone produced in fat cells, and also
in the placenta. Leptin controls weight by signaling the brain to eat
less when body fat stores are too high. If, for some reason the body cannot
produce enough leptin, or leptin cannot signal the brain to eat less,
this control is lost, and obesity occurs. The role of leptin replacement
as a treatment for obesity is currently being explored.
• Overeating. Overeating leads to weight gain,
especially if the diet is high in fat. Foods high in fat or sugar (e.g.,
fast food, fried food and sweets,) have high energy density (foods that
have a lot of calories in small amount of food). Epidemiology studies
have shown that diets high in fat contribute to weight gain.
• A diet high in simple carbohydrates. The role
of carbohydrates in weight gain is not clear. Carbohydrates increase blood
glucose levels, which in turn stimulate insulin release by the pancreas,
and insulin promotes the growth of fat tissue and can cause weight gain.
Some scientists believe that simple carbohydrates (sugars, fructose, desserts,
soft drinks, beer, wine, etc.) contribute to weight gain because they
are more rapidly absorbed into the blood stream than complex carbohydrates
(pasta, brown rice, grains, vegetables, raw fruits, etc.) and thus cause
a more pronounced insulin release after meals than complex carbohydrates.
This higher insulin release, some scientists believe, contribute to weight
gain.
• Frequency of eating. The relationship between
frequency of eating (how often you eat) and weight is somewhat controversial.
There are many reports of overweight people eating less often than people
with normal weight. Scientists have observed that people who eat small
meals four or five times daily, have lower cholesterol levels and lower
and/or more stable blood sugar levels than people who eat less frequently
(two or three) large meals daily. One possible explanation is that small
frequent meals produce stable insulin levels, whereas large meals cause
large spikes of insulin after meals.
• Slow metabolism. Women have less muscle than
men. Muscle burns more calories than other tissue (which includes fat).
As a result, women have a slower metabolism than men, and hence, have
a tendency to put on more weight than men, and weight loss is more difficult
for women. As we age, we tend to lose muscle and our metabolism slows,
therefore, we tend to gain weight as we get older particularly if we do
not reduce our daily caloric intake.
• Physical inactivity. Sedentary people burn fewer
calories than people who are active. The National Health and Examination
Survey (NHANES) showed that physical inactivity was strongly correlated
with weight gain in both sexes.
• Medications. Medications associated with weight
gain include certain antidepressants (medications used in treating depression),
anti-convulsants (medications used in controlling seizures such as carbamazepine
and valproate), diabetes medications (medications used in lowering blood
sugar such as insulin, sulfonylureas and thiazolidinediones), certain
hormones such as oral contraceptives and most corticosteroids such as
Prednisone. Weight gain may also be seen with some high blood pressure
medications and antihistamines.
• Psychological factors. For some people, emotions
influence eating habits. Many people eat excessively in response to emotions
such as boredom, sadness, stress or anger. While most overweight people
have no more psychological disturbances than normal weight people, about
30 percent of the people who seek treatment for serious weight problems
have difficulties with binge eating.
• Diseases such as hypothyroidism, insulin resistance, polycystic
ovary syndrome and Cushing's syndrome are also contributors to obesity. |
 |
What are the
health risks associated with obesity? |
|
Obesity
is not just a cosmetic consideration; it is a dire health dilemma directly
harmful to one's health. In the United States, roughly 300,000 deaths
per year are directly related to obesity, and more than 80% of these deaths
are in patients with a BMI (body mass index, which will be discussed later
in this article) over 30. Obesity also increases the risk of developing
a number of chronic diseases including:
• Insulin Resistance. Insulin is necessary for the transport of
blood glucose (sugar) into the cells of muscle and fat (which is then
used for energy). By transporting glucose into cells, insulin keeps the
blood glucose levels in the normal range. Insulin resistance (IR) is the
condition whereby the effectiveness of insulin in transporting glucose
(sugar) into cells is diminished. Fat cells are more insulin resistant
than muscle cells; therefore, one important cause of IR is obesity. The
pancreas initially responds to IR by producing more insulin. As long as
the pancreas can produce enough insulin to overcome this resistance, blood
glucose levels remain normal. This IR state (characterized by normal blood
glucose levels and high insulin levels) can last years. Once the pancreas
can no longer keep up with producing high levels of insulin, blood glucose
levels begin to rise, resulting in type 2 diabetes, thus IR is a pre-diabetes
condition. In fact scientists now believe that the atherosclerosis (hardening
of the arteries) associated with diabetes likely develops during this
IR period.
• Type 2 (adult-onset) diabetes. The risk of type 2 diabetes increases
with the degree and duration of obesity. Type 2 diabetes is associated
with central obesity; a person with central obesity has excess fat around
his/her waist, so that the body is shaped like an apple.
• High blood pressure (hypertension). Hypertension is common among
obese adults. A Norwegian study showed that weight gain tended to increase
blood pressure in women more significantly than in men. The risk of developing
high blood pressure is also higher in obese people who are apple shaped
(central obesity) than in people who are pear shaped (fat distribution
mainly in hips and thighs).
• High cholesterol (hypercholesterolemia)
• Stroke (cerebrovascular accident or CVA)
• Heart attack. The Nurses Health Study found that the risk of developing
coronary artery disease increased 3 to 4 times in women who had a BMI
greater than 29. A Finnish study showed that for every one kilogram (2.2
pounds) increase in body weight, the risk of death from coronary artery
disease increased by one percent. In patients who have already had a heart
attack, obesity is associated with an increased likelihood of a second
heart attack.
• Congestive heart failure
• Cancer. While not conclusively proven, some observational studies
have linked obesity to cancer of the colon in men and women, cancer of
the rectum and prostate in men, and cancer of the gallbladder and uterus
in women. Obesity may also be associated with breast cancer, particularly
in postmenopausal women. Fat tissue is important in the production of
estrogen, and prolonged exposure to high levels of estrogen increases
the risk of breast cancer.
• Gallstones
• Gout and gouty arthritis
• Osteoarthritis (degenerative arthritis) of the knees, hips, and
the lower back
• Sleep apnea
• Pickwickian syndrome (obesity, red face, underventilation, and
drowsiness)
What can be done about obesity?
All too often, obesity prompts a strenuous diet in the hopes
of reaching the "ideal body weight." Some amount of weight loss
may be accomplished, but the lost weight usually quickly returns. More
than 95% of the people who lose weight regain the weight within five years.
It is clear that a more effective, long-lasting treatment for obesity
must be found, lest obesity lead to oblivion. |
 |
Research articles
on Weight loss agents |
|
Diabetes Obes Metab.
2005 Jan;7(1):47-55.
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment
in hypertensive obese patients.
Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli
L, Fogari R.
Department of Internal Medicine and Therapeutics, University of Pavia, 2-27100
Pavia, Italy. giuderosa@tin.it
AIM: The aim of our study was to comparatively evaluate the efficacy
and safety of orlistat and sibutramine treatment in obese hypertensive
patients, with a specific attention to cardiovascular effects and to side
effects because of this treatment. METHODS: Patients were enrolled, evaluated
and followed at three Italian Centres of Internal Medicine. We evaluated
115 obese and hypertensive patients. (55 males and 60 females; 26 males
and 29 females, aged 50 +/- 4 with orlistat; 28 males and 30 females,
aged 51 +/- 5 with sibutramine). All patients took antihypertensive therapy
for at least 6 months before the study. We administered orlistat or sibutramine
in a randomized, controlled, double-blind clinical study. We evaluated
anthropometric variables, blood pressure and heart rate (HR) during 12
months of this treatment. RESULTS: A total of 113 completed the 4 weeks
with controlled energy diet and were randomized to double-blind treatment
with orlistat (n = 55) or sibutramine (n = 58). Significant body mass
index (BMI) improvement was present after 6 (p < 0.05), 9 (p < 0.02),
and 12 (p < 0.01) months in both groups, and body weight (BW) improvement
was obtained after 9 (p < 0.05) and 12 (p < 0.02) months in both
groups. Significant waist circumference (WC), hip circumference (HC) and
waist/hip ratio (W/H ratio) improvement was observed after 12 months (p
< 0.05, respectively) in both groups. Significant systolic blood pressure
(SBP) and diastolic blood pressure (DBP) improvement (p < 0.05) was
present in orlistat group after 12 months. Lipid profile [total cholesterol
(TC), low-density lipoprotein-cholesterol (LDL-C) and triglycerides] reduction
(p < 0.05, respectively) was observed in orlistat group and triglyceride
reduction (p < 0.05) in sibutramine group after 12 months. No significant
change was observed in sibutramine group during the study. No significant
HR variation was obtained during the study in both groups. Of the 109
patients who completed the study, 48.1% of patients in the orlistat group
and 17.5% of patients in the sibutramine group had side effects (p <
0.05 vs. orlistat group). Side-effect profiles were different in the two
treatment groups. All orlistat side effects were gastrointestinal events.
Sibutramine caused an increase in blood pressure (both SBP and DBP) in
two patients, but it has been controlled by antihypertensive treatment.
The vitamin changes were small and all mean vitamin and beta-carotene
values stayed within reference ranges. No patients required vitamin supplementation.
CONCLUSIONS: Both orlistat and sibutramine are effective on anthropometric
variables during the 12-month treatment; in our sample, orlistat has been
associated to a mild reduction in blood pressure, while sibutramine assumption
has not be associated to any cardiovascular effect and was generically
better tolerated than orlistat.
|
Int J Obes Relat Metab
Disord. 2005 Mar 01.
Orlistat in responding obese type 2 diabetic patients: meta-analysis findings
and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland.
Ruof J, Golay A, Berne C, Collin C, Lentz J, Maetzel A.
[1] 1Health Services Research Unit, Division of Rheumatology, Center of
Internal Medicine, Hannover Medical School, Hannover, Germany [2] 2Global
Health Economics Department, Roche Pharmaceuticals, Basel, Switzerland.
OBJECTIVE:: The aim of this study is to review the clinical and economic
rationale for the reimbursement of orlistat in responding obese patients
with type 2 diabetes. METHODS:: Data from seven randomized controlled
clinical trials of orlistat in overweight and obese patients with type
2 diabetes were pooled. A subgroup analysis involving patients who achieved
a response (defined as a weight loss of >/=5% after 12 weeks of treatment)
was conducted. The outcomes of the pooled analysis were then used to construct
a Markov health economic model covering an 11-y period. The incidences
of diabetes-related micro- and macrovascular complications were derived
from the United Kingdom Prospective Diabetes Study. The effects of changes
in body mass index, and the impact of micro- and macrovascular complications
on utilities were derived from published sources. Publicly available cost
data were used and are presented here in 2001 Euros. Discounting of 3%
was applied. A probabilistic sensitivity analysis was conducted to examine
the robustness of results. RESULTS:: A total of 1249 patients treated
with orlistat and 1230 given placebo were eligible for the intent-to-treat
analysis. At the end of the study period, 23% of orlistat patients achieved
a weight reduction of >/=5%. These patients showed a mean decrease
in HbA1C of 1.16%, a weight reduction of 8.6 kg, a reduction in total
cholesterol of 5.3% and a reduction in systolic blood pressure of 5.2
mmHg. The base-case economic analysis revealed costs per quality-adjusted
life year gained of \[euro]14 000 in Sweden and \[euro]13 600 in Switzerland.
CONCLUSION:: The data presented here support the utilization and reimbursement
of orlistat in overweight and obese diabetic patients who respond to the
treatment.International Journal of Obesity advance online publication,
1 March 2005; doi:10.1038/sj.ijo.0802925.
|
Prim Care. 2003 Jun;30(2):427-40.
Orlistat in the treatment of obesity.
Hollander P.
Baylor Hospital, Wadley Tower, Suite 656, 3600 Gaston Avenue, Dallas, TX
75246, USA.
Orlistat has been well studied in several populations, including patients
who do and do not have type 2 diabetes and in patients who have impaired
glucose tolerance. Overall, modest, but significant, weight loss was seen
in all three groups of patients with favorable effects on the comorbidities
of obesity. Orlistat has not been associated with a serious adverse event
profile, and the mild GI effects that are seen in some patients are well
tolerated. In obese patients who do not have diabetes, weight loss is
achieved and maintained as shown in the 2-year studies. Moreover, as was
well documented in the Swedish multi-morbidity study, favorable treatment
effects on the constituents of the metabolic syndrome are seen. Orlistat,
together with a hypocaloric diet, was proven to be effective in preventing
diabetes in patients who had impaired glucose tolerance. The addition
of orlistat resulted in significant weight loss and significance decreases
in levels of HbA1c in patients who had type 2 diabetes who were treated
with antihyperglycemic drugs. Studies showed that it is possible to identify
early which patients may respond best to treatment. Orlistat offers an
attractive treatment option for obese patients who do and do not have
diabetes and as a combination drug for treatment of obese patients who
have type 2 diabetes.
|
Int J Obes Relat Metab
Disord. 2002 Feb;26(2):262-73
PPharmacotherapy for obesity: a quantitative analysis of four decades of
published randomized clinical trials.
Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M.
University of Missouri-Kansas City and Mid America Heart Institute, St Luke's
Hospital, Kansas City, Missouri 64110, USA
AIM: This article provides the first comprehensive meta-analysis of randomized
clinical trials of medications for obesity. METHOD: Based on stringent
inclusionary criteria, a total of 108 studies were included in the final
database. Outcomes are presented for comparisons of single and combination
drugs to placebo and for comparisons of medications to one another. RESULT:
Overall, the medications studied produced medium effect sizes. Four drugs
produced large effect sizes (ie d>0.80; amphetamine, benzphetamine,
fenfluramine and sibutramine). The placebo-subtracted weight losses for
single drugs vs placebo included in the meta-analysis never exceeded 4.0
kg. No drug, or class of drugs, demonstrated clear superiority as an obesity
medication. Effects of methodological factors are also presented along
with suggestions for future research. |
Rev Neurol. 2002 Apr
1-15;34(7):612-7.
The evolution of use of anti-Parkinson drugs in Spain
Montane E, Vallano Ferraz A, Castel JM.
Servicio de Farmacologia Clinica, Hospital Universitario Vall d'Hebron,
Barcelona, Espana.
INTRODUCTION. In recent years new anti Parkinson drugs have been marketed
and there has been controversy over the safety of some drugs. OBJECTIVE.
To analyze the evolution of the consumption of anti Parkinson drugs and
the effect of the newer drugs. PATIENTS AND METHODS. A study of the consumption
of anti Parkinson drugs (1989 1998). Data were obtained from the ECOM
database of the Ministry of Health and TEMPUS of the National Statistics
Institute. The drugs were classified using the Anatomo Therapeutic Clinical
Classification (ATC). Consumption was expressed in defined daily dosage
(DDD) and the costs in euros. The drugs marketed since 1990 were classified
as new drugs and the others as classical drugs. RESULTS. The total consumption
of drugs increased from 1.92 DDD/1,000 inhabitants/day in 1989 to 3.64
DDD/1,000 inhabitants/day in 1998. The drugs showing the greatest increase
were selegiline, pergolide and levodopa. The total pharmaceutical expenses
tripled. There was a smaller increase in the consumption of new drugs
(1.2% of the total in 1991 and 6.6% in 1998) than in their costs (6.7%
of the total in 1991 and 38.8% in 1998). The cost per DDD of the new drugs
increased five times (1989: 2.55 euros and 1998: 13.59 euros) and that
of the classical drugs was similar (1989: 0.54 euros and 1998: 0.62 euros).
CONCLUSIONS. The total consumption of anti Parkinson drugs has progressively
increased. The consumption of selegiline has also increased in spite of
controversy over its safety. The new drugs have a major economic effect. |
Ann Pharm Fr. 1990;48(2):70-80.
Working hypothesis for the effect of GABAergic, glycinergic or glutamatergic
drugs in the treatment of Parkinson disease
Vamvakides A.
Laboratoire Chropi, Paris.
The data obtained during the past decade in experimental and clinical
pharmacology show that the GABAergic drugs, with central activity, do
not ameliorate the symptoms of the Parkinson's disease (PD), but would
worsen the akineto-rigid syndrome, the dyskinesias and the deteriorating
mental status in the later stages of the PD. On the other hand, recent
data of experimental pharmacology suggest the possibility that glycinergic
or glutamatergic derivatives, with central activity, would have a beneficial
effect on the syndromes of the later stages of PD (declining efficacy
of L-DOPA, dyskinesias, deteriorating mental status), which constitute,
with the fluctuation of the response to L-DOPA, ("on-off" effects),
the major problems of the PD's treatment. Some theoretical and experimental
data also suggest the possibility of a beneficial effect of the glutamatergic
drugs in the treatment of the "on-off" effects. |
Neurology 1985 Apr;35(4):571-3
Motor function in the normal aging population: treatment
with levodopa Newman RP, LeWitt PA, Jaffe M,
Calne DB, Larsen TA
In normal elderly humans there is progressive motor dysfunction and loss
of nigrostriatal neurons and brain dopamine similar to, although of a milder
degree than, that seen in Parkinson's disease. Ten healthy elderly volunteers
were given carbidopa/levodopa or placebo in a double-blind crossover study.
We measured movement velocity, reaction time, tremor, visual evoked response
(VER), and electroretinography (ERG). Significant changes were seen only
in ERG. Motor functions and VER were unchanged. Although there appeared
to be pharmacologic activity (ie, changes in ERG), levodopa, in adequate
antiparkinson dosage, had no impact on the mild extrapyramidal impairment
of normal elderly subjects. |
|